Evidence map›Paper›PMID 22880034›Full record

ArticlePloS one2012

Identification of CD166 as a surface marker for enriching prostate stem/progenitor and cancer initiating cells.

Jing Jiao, Antreas Hindoyan, Shunyou Wang, Linh M Tran, Andrew S Goldstein, Devon Lawson, Donghui Chen, Yunfeng Li, Changyong Guo, Baohui Zhang and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 1 pooled it
9.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 1 synthesis or guideline pooled it, 110 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Advances in Prostate Cancer Biomarkers and Probes.Cyborg and bionic systems (Washington, D.C.) · 2024
    Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Recent advances in tissue stem cells.Science China. Life sciences · 2021
    Review

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Jing JiaoDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California, United States of America.
Antreas Hindoyan
Shunyou Wang
Linh M Tran
Andrew S Goldstein
Devon Lawson
Donghui Chen
Yunfeng Li
Changyong Guo
Baohui Zhang
Ladan Fazli
Martin Gleave
Owen N Witte
Isla P Garraway
Hong Wu
University of California, Los Angeles · USHoward Hughes Medical Institute · USInstitute for Molecular Medicine · USUniversity of British Columbia · CABroad Center · US

Funding

Study of cell-of-origin and cancer stem cells in prostatic adenocarcinomaR01CA121110 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WU, HONG · 2008 to 2012
$1.7M
PTEN and Prostate Cancer ProgressionR01CA107166 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WU, HONG · 2004 to 2008
$1.7M
Howard Hughes Medical InstituteNCI NIH HHS R01 CA107166NCI NIH HHS R01 CA121110
6 · The paper itself

Abstract

New therapies for late stage and castration resistant prostate cancer (CRPC) depend on defining unique properties and pathways of cell sub-populations capable of sustaining the net growth of the cancer. One of the best enrichment schemes for isolating the putative stem/progenitor cell from the murine prostate gland is Lin(-);Sca1(+);CD49f(hi) (LSC(hi)), which results in a more than 10-fold enrichment for in vitro sphere-forming activity. We have shown previously that the LSC(hi) subpopulation is both necessary and sufficient for cancer initiation in the Pten-null prostate cancer model. To further improve this enrichment scheme, we searched for cell surface molecules upregulated upon castration of murine prostate and identified CD166 as a candidate gene. CD166 encodes a cell surface molecule that can further enrich sphere-forming activity of WT LSC(hi) and Pten null LSC(hi). Importantly, CD166 could enrich sphere-forming ability of benign primary human prostate cells in vitro and induce the formation of tubule-like structures in vivo. CD166 expression is upregulated in human prostate cancers, especially CRPC samples. Although genetic deletion of murine CD166 in the Pten null prostate cancer model does not interfere with sphere formation or block prostate cancer progression and CRPC development, the presence of CD166 on prostate stem/progenitors and castration resistant sub-populations suggest that it is a cell surface molecule with the potential for targeted delivery of human prostate cancer therapeutics.

Indexed as

Activated-Leukocyte Cell Adhesion MoleculeAnimalsBiomarkers, TumorCastrationCell MembraneDisease Models, AnimalDisease ProgressionEpitheliumGene DeletionGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiceNeoplastic Stem CellsProstateActivated-Leukocyte Cell Adhesion MoleculeBiomarkers, TumorPTEN PhosphohydrolasePten protein, mouse

Identifiers

PMID22880034
PMCPMC3411798
OpenAlexW1973987878

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.